Get the Stockscreener App
6.1378
5.93%
-0.3922
Jasper Therapeutics Inc stock is traded at $6.1378, with a volume of 182.24K.
It is down -5.93% in the last 24 hours and down -65.31% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$6.53
Open:
$6.5
24h Volume:
182.24K
Relative Volume:
0.40
Market Cap:
$97.96M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.9923
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
+1.37%
1M Performance:
-65.31%
6M Performance:
-62.24%
1Y Performance:
-64.90%
1-Day Range:
$6.12
$6.6368
1-Week Range:
$5.81
$7.06
52-Week Range:
$5.25
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
6.14 | 97.96M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.40 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.48 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.55 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
JSPR’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle
Selling Buzz: Jasper Therapeutics Inc [JSPR] Chief Operating Officer Mahal Jeetinder Singh sells 900 shares of the company – Knox Daily - Knox Daily
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire
Knightscope Achieves Full FedRAMP® Authorization, Unlocking Federal Growth - The Globe and Mail
Inside Jasper's Revolutionary Mast Cell Therapy: Key Updates Coming at Major Healthcare Conference - StockTitan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
How to Take Advantage of moves in (JSPR) - Stock Traders Daily
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $67.75 - Defense World
Insider Selling in Tech Stocks Spikes in Q4 - The Globe and Mail
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Cantor Fitzgerald Forecasts JSPR FY2025 Earnings - Defense World
Research Analysts Set Expectations for JSPR FY2025 Earnings - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Barclays PLC - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Rises By 12.1% - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1% - MarketBeat
HC Wainwright Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00 - Defense World
What is HC Wainwright’s Forecast for JSPR Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for JSPR Q1 Earnings? - MarketBeat
Jane Street Group LLC Takes $251,000 Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
What is HC Wainwright’s Estimate for JSPR FY2029 Earnings? - Defense World
Royal Bank of Canada Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00 - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Stock summary: Jasper Therapeutics witnessed loss overall loss of 67.19% throughout the week - Business Upturn
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright - MarketBeat
What is HC Wainwright's Forecast for JSPR FY2029 Earnings? - MarketBeat
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada - MarketBeat
BMO maintains Jasper Therapeutics Outperform rating By Investing.com - Investing.com Australia
Why Jasper Therapeutics stock plunged 60% in one trading session - Dataconomy
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes urticaria stock outlook - Investing.com India
Quantum Computing Stocks Tumble: Market Reacts to NVIDIA CEO Statement – Market - HPBL
Trading (JSPR) With Integrated Risk Controls - Stock Traders Daily
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy By Investing.com - Investing.com Canada
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy - Investing.com India
Buy rating upheld for Jasper Therapeutics stock as briquilimab progresses in trials - Investing.com Nigeria
Oppenheimer maintains $80 target on Jasper Therapeutics stock - Investing.com India
BMO maintains Jasper Therapeutics Outperform rating - Investing.com
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Jasper Therapeutics stock dips following early trial results for chronic hives treatment - Investing.com Canada
Jasper Therapeutics stock tumbles after study data - Investing.com
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria - GlobeNewswire
Jasper's Briquilimab Achieves 100% Complete Response in Chronic Urticaria Trial Results - StockTitan
Jasper Therapeutics (NASDAQ:JSPR) Earns Market Outperform Rating from JMP Securities - Defense World
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes urticaria stock outlook - Investing.com Nigeria
Jasper Therapeutics' SWOT analysis: briquilimab stock poised for growth in mast cell disease market - Investing.com Canada
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jasper Therapeutics Inc Stock (JSPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):